Results 1 to 10 of about 3,556,677 (271)

Rituximab and Cytokine Release Syndrome [PDF]

open access: yesCase Reports in Oncology, 2012
Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated
Hrishikesh S. Kulkarni   +1 more
doaj   +5 more sources

Rituximab induced cytokine release syndrome in an MS patient: A case report

open access: yesClinical Case Reports, 2021
Cytokine release syndrome with rituximab has been reported in certain diseases, however, it is rarely reported in MS patients treated with rituximab. The treating physician should suspect the syndrome when typical signs and symptoms appear.
Masoud Etemadifar   +4 more
doaj   +2 more sources

Cytokine release syndrome

open access: yesJournal of Pediatric Critical Care
Cytokine release syndrome (CRS) is a severe, potentially life-threatening immune-mediated condition characterized by excessive cytokine secretion leading to systemic inflammation and multiorgan dysfunction.
Rachit Mehta, Indira Jayakumar
doaj   +3 more sources

Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm

open access: yesFrontiers in Immunology, 2020
SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS).
Jesus Gonzalez-Rubio   +6 more
doaj   +2 more sources

Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2020
In recent years, cancer treatment has evolved, and new therapies have been introduced with significant improvement in prognosis. The immunotherapies stand out owing to their efficacy and remission rate. Chimeric antigen receptor (CAR) T-cell therapy is a
Cesar Clavijo Simbaqueba   +9 more
doaj   +1 more source

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome

open access: yesCancer Biology & Medicine, 2022
Cytokine release syndrome (CRS) is a major obstacle to the widespread clinical application of chimeric antigen receptor (CAR) T cell therapies. CRS can also be induced by infections (such as SARS-CoV-2), drugs (such as therapeutic antibodies), and some ...
Hanfei Guo, Lei Qian, Jiuwei Cui
doaj   +1 more source

Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection

open access: yesmBio, 2021
The outbreak of SARS-CoV-2 infection has enormously impacted our lives. Clinical evidence has implicated the emergence of cytokine release syndrome as the prominent cause of mortality in COVID-19 patients.
Najmeh Bozorgmehr   +10 more
doaj   +1 more source

Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia

open access: yesCase Reports in Oncology, 2022
Cytokine release syndrome (CRS) is one of the major acute complications caused by massive cytokine release after chimeric antigen receptor (CAR) T-cell therapy. Patients with tumor masses were considered at high risk of local CRS induced by the expansion
Haruko Shima   +7 more
doaj   +1 more source

Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

open access: yesEuropean Journal of Inflammation, 2022
Adoptive immunotherapy has recently garnered widespread interests owing to the successful application of chimeric antigen receptor T cell therapy.
Xiaoxue Shi, Hongfang Wu
doaj   +1 more source

Modern Approaches to the Diagnosis and Treatment of Cytokine Release Syndrome Following CAR T-Cell Therapy

open access: yesМедицина и биотехнологии
Introduction. Oncological diseases remain one of the leading causes of mortality worldwide. CAR T-cell therapy has demonstrated high efficacy in the treatment of B-cell leukaemias, lymphomas, and multiple myeloma.
Alexander M. Tsurkan   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy